News
ARVN
8.83
-2.75%
-0.25
Weekly Report: what happened at ARVN last week (0511-0515)?
Weekly Report · 6h ago
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)
Simply Wall St · 2d ago
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN) and SCHOTT Pharma AG & Co. KGaA (Milan: IT:1SXP)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN)
TipRanks · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arvinas Holding Company (ARVN) and BridgeBio Oncology Therapeutics (BBOT)
TipRanks · 4d ago
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters · 4d ago
ARVINAS INC <ARVN.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $9 FROM $18
Reuters · 4d ago
Arvinas (ARVN) Q1 Loss Of US$0.90 Per Share Challenges Bullish Margin Narratives
Simply Wall St · 4d ago
Arvinas price target raised to $16 from $14 at BofA
TipRanks · 4d ago
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Benzinga · 4d ago
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
TipRanks · 5d ago
Arvinas Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
Barclays Maintains Overweight on Arvinas, Raises Price Target to $20
Benzinga · 5d ago
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ovid Therapeutics (OVID) and Arvinas Holding Company (ARVN)
TipRanks · 5d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Verrica Pharmaceuticals (VRCA) and Arvinas Holding Company (ARVN)
TipRanks · 5d ago
Arvinas Price Target Raised to $18.00/Share From $16.00 by BTIG
Dow Jones · 5d ago
Arvinas Is Maintained at Buy by BTIG
Dow Jones · 5d ago
BTIG Maintains Buy on Arvinas, Raises Price Target to $18
Benzinga · 5d ago
ARVINAS <ARVN.O>: BARCLAYS RAISES TARGET PRICE TO $20 FROM $18
Reuters · 5d ago
More
Webull provides a variety of real-time ARVN stock news. You can receive the latest news about Arvinas through multiple platforms. This information may help you make smarter investment decisions.
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.